AbbVie (ABBV) Shares Fall 6% Following Revenue Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
AbbVie to pay up to $2.37 billion to settle U.S. opioid claims
July 29, 2022 7:43 AM EDTBy Manas Mishra and Brendan Pierson
(Reuters) -AbbVie Inc has agreed to pay up to $2.37 billion to resolve thousands of U.S. lawsuits against its Allergan unit over the marketing of opioid painkillers, state officials announced on Friday.
If finalized, the deal could end more than 3,000 lawsuits by state and local governments around the country. It includes settlements the drugmaker has already reached with states, including $200 million for New York.
"We've worked hard to get the... More
AbbVie (ABBV) Tops Q2 EPS by 3c, Maintains FY EPS Guidance
July 29, 2022 7:42 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $3.37, $0.03 better than the analyst estimate of $3.34. Revenue for the quarter came in at $14.58 billion versus the consensus estimate of $14.67 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $13.78-$13.98, versus the consensus of... More
AbbVie (ABBV) Announces EU Approval of RINVOQ as Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
July 29, 2022 5:52 AM EDTAbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*1
"For years, healthcare providers and patients have had limited treatment options to manage axial spondyloarthritis, which can cause back pain, stiffness, and... More
AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Crohn's Disease
July 27, 2022 8:45 AM EDTAbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.4,11
"Crohn's disease can be... More
